Assessing the prevalence of extra-pulmonary tuberculosis among human immunodeficiency infected patients at a hospital in Kwazulu-Natal, South Africa. A retrospective cross-sectional study.
DOI:
https://doi.org/10.51168/sjhrafrica.v7i3.2452Keywords:
Extrapulmonary Tuberculosis, Human Immunodeficiency Virus, Coinfection, prevalence, Infectious disease implications, Immunocompromised individualsAbstract
Introduction
The co-epidemic of Human Immunodeficiency Virus (HIV) and Tuberculosis (TB), Extrapulmonary Tuberculosis (EPTB) pose a major health issue in KwaZulu Natal (KZN) South Africa (SA). Despite improvements in HIV care, EPTB continues to affect immunocompromised individuals. Therefore, this study aimed to bridge this knowledge gap by determining the prevalence, and risk factors associated with EPTB prevalence among HIV-infected patients in KZN.
Methodology
Patient results for those tested for EPTB from January to December 2022, were examined. Key variables included demographic information including age, gender, geographic location. HIV viral load, CD4 count, and GeneXpert tuberculosis were the test results analysed. To ensure accuracy, the dataset underwent rigorous cleaning to exclude incomplete records and duplicates. Microsoft Excel 2019 facilitated descriptive and graphical analysis to illustrate trends. Spearman's correlation was used to examine associations among continuous variables, with statistical significance assessed using p-values and confidence intervals
Results
Among 609 analyzed HIV-positive patient results, 86 (14.1%) had EPTB. Most cases 382 (62.7%) originated from the uGu district, with the highest prevalence observed among males aged 40-64 years. EPTB manifestation was notably high in lymph node aspirate specimens. Additionally, detectable viral loads and moderately suppressed CD4 counts indicated advanced HIV progression, increasing susceptibility to EPTB co-infections.
Conclusion
This study shows a significant burden of EPTB among HIV-infected individuals in KZN, especially in older patients with high viral loads. Targeted interventions for early detection, screening programs, and gender-specific approaches are crucial to reducing morbidity and mortality.
Recommendation
Strengthening antiretroviral therapy programmes is essential, as effective viral suppression substantially reduces the risk of TB among people living with HIV by lowering susceptibility to infection.
References
Angazu L, Smith J, Johnson P, et al. The dual burden of HIV and tuberculosis in Southern Africa: A public health crisis. J Infect Dis. 2023;45(3):123-135.
Campbell T. Investigating the emergence and spread of tuberculosis in South Africa.
Weitzestein R, Brown T, Green K, et al. Global trends in TB/HIV co-infection: A focus on Southern Africa. Int J Tuberc Lung Dis. 2023;27(2):89-97.
Wang Y, Jing W, Liu J, Liu M. Global trends, regional differences and age distribution for the incidence of HIV and tuberculosis co-infection from 1990 to 2019: results from the global burden of disease study 2019. Infectious Diseases. 2022 Nov 2;54(11):773-83.
Ross J, Mkhize N, Dlamini S, et al. KwaZulu-Natal as the epicenter of HIV and TB in South Africa: Challenges and opportunities. SA Med J. 2023;113(4):56-63.
Rolo D, Fernandes S, Costa J, et al. Increased risk of extrapulmonary tuberculosis in HIV-infected individuals: A systematic review. Clin Infect Dis. 2023;76(5):789-797.
Alemu A, Yesuf A, Gebrehanna E, Zerihun B, Getu M, Worku T, Bitew ZW. Incidence and predictors of extrapulmonary tuberculosis among people living with Human Immunodeficiency Virus in Addis Ababa, Ethiopia: A retrospective cohort study. PloS one. 2020 May 6;15(5):e0232426.
Wada T, Nakamura K, Yamamura M, et al. Immune dysfunction in HIV and its impact on tuberculosis susceptibility. J Immunol Res. 2020;2020:1-10.
Tiberi S, Utjesanovic N, Galvin J, Centis R, D'Ambrosio L, van den Boom M, Zumla A, Migliori GB. Drug resistant TB–latest developments in epidemiology, diagnostics and management. International Journal of Infectious Diseases. 2022 Nov 1;124:S20-5.
Narendran G, Swaminathan S, Menon P, et al. Opportunistic infections in HIV-TB co-infected patients: A clinical perspective. Lancet Infect Dis. 2022;22(8):e200-e210 .
Soni R, Patel K, Gupta A, et al. Diagnostic challenges of extrapulmonary tuberculosis in resource-limited settings. J Clin Tuberc Other Mycobact Dis. 2023;30:100345.
Goel S, Kumar P, Singh A, et al. Immune reconstitution inflammatory syndrome in HIV-TB co-infected patients: A review. AIDS Res Ther. 2023;20(1):45.
Xavier A, Thomas B, Mathew R, et al. Clinical outcomes of immune reconstitution inflammatory syndrome in HIV-TB co-infection. J Infect Public Health. 2023;16(3):456-463.
Bowen LN, Smith B, Reich D, Quezado M, Nath A. HIV-associated opportunistic CNS infections: pathophysiology, diagnosis and treatment. Nature Reviews Neurology. 2016 Nov;12(11):662-74.
Obeagu E, Ochei K, Nwachukwu B, et al. Unusual pathogens and clinical presentations in HIV-infected individuals: A case series. Afr J Clin Exp Microbiol. 2024;25(1):12-18.
Aribi M, Bouzid K, Haddad S, et al. Delayed diagnosis and treatment of HIV: Implications for disease progression and mortality. J Acquir Immune Defic Syndr. 2023;92(4):321-329.
Kumar V, Singh R, Sharma M, et al. Prevalence of extrapulmonary tuberculosis in HIV-infected individuals: A meta-analysis. PLoS ONE. 2020;15(7):e0236547 .
Sharma S, Mohan A, Singh S, et al. Extrapulmonary tuberculosis in HIV-infected patients: A review of clinical and epidemiological features. Indian J Med Res. 2019;149(2):185-195.
World Health Organization (WHO). Global tuberculosis report 2021. Geneva: WHO; 2021.
Castle B, Moyo S, Dube S, et al. Gaps in understanding the epidemiology of HIV and extrapulmonary tuberculosis co-infection. BMC Infect Dis. 2023;23(1):456.
Bulti A, Tesfaye W, Abebe G, et al. Strategies to address the burden of HIV and extrapulmonary tuberculosis co-infection: A call for action. J Glob Health. 2024;14:01001.
Gupte AN, Kadam D, Sangle S, Rewari B, Salvi S, Chavan A, et al. High burden of prevalent and recently acquired tuberculosis among people living with HIV on antiretroviral therapy. J Acquir Immune Defic Syndr. 2019;80(5):535-41.
Zurcher K, Ballif M, Kiertiburanakul S, Chenal H, Yotebieng M, Grinsztejn B, et al. Outcomes of HIV-positive patients with tuberculosis in Asia and Africa: A multicohort study. J Acquir Immune Defic Syndr. 2019;80(5):542-9.
Achwoka D, Waruru A, Chen TH, Masamaro K, Ngugi E, Kimani M, et al. Noncommunicable disease burden among HIV patients in care: A national retrospective longitudinal analysis of HIV-treatment outcomes in Kenya, 2003–2013. BMC Public Health. 2020;20(1):1-12.
Hamada Y, Lujan J, Schenkel K, Ford N, Getahun H. Sensitivity and specificity of WHO-defined immunological failure in predicting virological failure in HIV-infected adults on antiretroviral therapy: A systematic review and meta-analysis. PLoS One. 2021;16(3):e0248229.
Wondmeneh TG, Mekonnen D. Delayed diagnosis and treatment of tuberculosis in sub-Saharan Africa: A systematic review. BMC Infect Dis. 2023;23(1):1-10.
Shivakoti R, Sharma D, Mamoon G, Pham K. Prevalence and risk factors of tuberculosis among people living with HIV/AIDS in Asia: A systematic review and meta-analysis. PLoS One. 2017;12(9):e0184963.
Sungkanuparph S, Kiertiburanakul S, Manosuthi W, Kiertiburanakul S, Thakkinstian A. Initiation of antiretroviral therapy in advanced HIV disease: A review of the evidence and recommendations. J Int AIDS Soc. 2017;20(1):21510.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Sphelele Mlambo, Nokukhanya Thembane, Ziningi Nobuhle Jaya

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
















